CureVac Announces Voting Results of Extraordinary General Meeting (English only)
CureVac N.V., a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the voting results of the Company’s extraordinary general meeting.
The shareholders of the Company voted in favor of all proposals. The proposals voted in favor for included the appointment of Dr. Alexander Zehnder as CEO effective April 1st, 2023 and confirmation of the appointment of Dr. Myriam Mendila as CDO effective February 1st, 2023.
A table containing tabulations of the votes casted is expected to be released in the coming days.